Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer

被引：0
|
作者：
Shtivelband, Mikhail
Spigel, David R.
Gerber, David E.
Jain, Minish Mahendra
Ponomarova, Olga V.
Giorgadze, Davit
Shan, Joseph
Menander, Kerstin B.
Belani, Chandra Prakash
机构：
[1] Ironwood Canc & Res Ctr, Chandler, AZ USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] UT Southwestern Med Ctr, Dallas, TX USA
[4] Ruby Hall Clin, Pune, Maharashtra, India
[5] RE Kavetsky Inst Expt Pathol Oncol & Radiobiol, Kiev, Ukraine
[6] Chemotherapy & Immunotherapy Clin, Tbilisi, Georgia
[7] Peregrine Pharmaceut Inc, Tustin, CA USA
[8] Penn State Hershey Canc Inst, Hershey, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8095
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [32] A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer
    Talbot, Denis C.
    von Pawel, Joachim
    Cattell, Emma
    Yule, S. Murray
    Johnston, Claire
    Zandvliet, Anthe S.
    Huitema, Alwin D. R.
    Norbury, Chris J.
    Ellis, Paul
    Bosquee, Leon
    Reck, Martin
    CLINICAL CANCER RESEARCH, 2007, 13 (06) : 1816 - 1822
  • [33] Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial
    Radhakrishnan, A.
    Bitran, J. D.
    Milton, D. T.
    Tolzien, K.
    Hallmeyer, S.
    Nabhan, C.
    JOURNAL OF CHEMOTHERAPY, 2009, 21 (04) : 439 - 444
  • [34] Second-line therapy of squamous non-small cell lung cancer: an evolving landscape
    Lazzari, Chiara
    Karachaliou, Niki
    Gregorc, Vanesa
    Bulotta, Alessandra
    Gonzalez-Cao, Maria
    Verlicchi, Alberto
    Altavilla, Giuseppe
    Rosell, Rafael
    Santarpia, Mariacarmela
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2017, 11 (06) : 469 - 479
  • [35] Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer:: A phase II trial
    Crinò, L
    Mosconi, AM
    Scagliotti, GV
    Selvaggi, G
    Rinaldi, M
    Della Giulia, M
    Gridelli, C
    Calandri, C
    De Marinis, F
    Noseda, M
    Tonato, M
    SEMINARS IN ONCOLOGY, 1998, 25 (04) : 23 - 26
  • [36] Randomized, placebo-controlled, phase II trial of EGFR and COX-2 inhibition in advanced non-small cell lung cancer
    Reckamp, K. L.
    Koczywas, M.
    Cristea, M. C.
    Dowell, J.
    Gardner, B.
    Milne, G.
    Rad, S. Fouladi
    Figlin, R. A.
    Elashoff, R.
    Dubinett, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [37] A phase II, double-blind, randomized study of enzastaurin versus placebo concurrently with pemetrexed as second-line therapy in patients with advanced or metastatic non-small cell lung cancer
    von Pawel, Joachim
    Barlesi, Fabrice
    Soria, Jean-Charles
    Bearz, Alessandra
    Barata, Fernando
    Park, Keunchil
    Zhao, Yan D.
    Chouaki, Nadia
    Iscoe, Neill
    Bepler, Gerold
    Chiappori, Alberto
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S384 - S385
  • [38] Docetaxel versus docetaxel plus irinotecan as second line chemotherapy in advanced non-small cell lung cancer (NSCLC): A randomized phase II trial.
    Pectasides, D
    Farmakis, D
    Pectasides, M
    Kostopoulou, V
    Nikolaou, M
    Koumpou, M
    Gaglia, A
    Kountourakis, P
    Mylonakis, N
    Economopoulos, T
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 625S - 625S
  • [39] AFLIBERCEPT IN COMBINATION WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC): FINAL RESULTS OF A MULTINATIONAL PLACEBO-CONTROLLED PHASE III TRIAL (EFC10261-VITAL)
    Novello, Silvia
    Ramlau, Rodryg
    Gorbunova, Vera A.
    Ciuleanu, Tudor E.
    Ozguroglu, Mustafa
    Goksel, Tuncay
    Baldotto, Clarissa
    Bennouna, Jaafar
    Shepherd, Frances A.
    Scagliotti, Giorgio
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S470 - S470
  • [40] CLINICAL BENEFITS OF SEQUENTIAL ADMINISTRATION OF DOCETAXEL AND INTERMITTENT ERLOTINIB AS A SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC), A PHASE II RANDOMIZED STUDY
    Juan, O.
    Aparisi Aparisi, F. D. A.
    Sanchez, A.
    Giner Marco, V.
    Munoz Langa, J.
    Esquerdo, G.
    Lopez, A.
    Garde, J.
    Garcia Sanchez, J.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S61 - S61
12345